Amneal Pharmaceuticals upgraded by The Goldman Sachs Group with a new price target

3/15/21 8:10:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

The Goldman Sachs Group upgraded Amneal Pharmaceuticals from Sell to Buy and set a new price target of $6.50 from $4.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMRX

Date	Price Target	Rating	Analyst
6/6/2025	$12.00	Buy	Goldman
2/24/2025	$9.00 → $12.00	Neutral → Overweight	Analyst
9/6/2024	$9.00	Underweight → Neutral	JP Morgan